Share Price | Hannah Joseph Hospital Ltd Stock Analysis & Recommendation

Q: Who are the peers of the Hannah Joseph?

Peers: The peers of Hannah Joseph are Asarfi Hospital, Lotus Eye Hospit, Aashka Hospitals, Abate As Indust, Vaidya Sane, Aprameya Enginee, Chandan Healthca, KHFM Hospitality, Unihealth Hosp, and Nephro Care.Quality Snapshot: Excellent management risk is observed at Aprameya Enginee, while Average management risk is found at Asarfi Hospital, Vaidya Sane, Chandan Healthca, and Unihealth Hosp. Below Average management risk is noted at Lotus Eye Hospit, Aashka Hospitals, Abate As Indust, KHFM Hospitality, and Nephro Care. Growth is Excellent at Chandan Healthca and Unihealth Hosp, while Good growth is seen at Asarfi Hospital and Vaidya Sane. Below Average growth is present at Lotus Eye Hospit, Aashka Hospitals, Abate As Indust, and KHFM Hospitality, and the rest have Average growth.Return Snapshot: The peer with the highest 1-year return is Lotus Eye Hospit at 66.04%, while Aashka Hospitals has the lowest at -24.05%. Hannah Joseph's 1-year return is not available for comparison. Additionally, Aashka Hospitals and Abate As Indust have negative six-month returns.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.0 k (-64.29%) Volume

Shareholding (Feb 2026)

FII

2.39%

Held by 2 FIIs

DII

10.15%

Held by 0 DIIs

Promoter

68.83%

Why is Hannah Joseph Hospital Ltd falling/rising?

23-Jun-2026

As of 22-Jun, Hannah Joseph Hospital Ltd's stock price is rising to 99.80, reflecting a 2.78% increase and strong performance over the past week. The stock is trading above all key moving averages, indicating bullish momentum despite a decline in delivery volume.

View full answer

Which are the latest news on Hannah Joseph?

23-Jun-2026

When is the next results date for Hannah Joseph Hospital Ltd?

Who are the peers of the Hannah Joseph?

11-Jun-2026

Hannah Joseph's peers include Asarfi Hospital, Lotus Eye Hospital, Aashka Hospitals, and others. Key insights show excellent management risk at Aprameya Engineering, while Lotus Eye Hospital leads in 1-year returns at 66.04%, and Aashka Hospitals has the lowest at -24.05%.

View full answer

When is the next results date for Hannah Joseph Hospital Ltd?

19-May-2026

The next results date for Hannah Joseph Hospital Ltd is 29 May 2026.

View full answer

Compare Hannah Joseph with Similar Stocks

Lotus Eye Hospit Aashka Hospitals Aprameya Enginee

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Hospital

Market cap

INR 227 Cr (Micro Cap)

P/E

20.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.17

Return on Equity

11.48%

Price to Book

2.33

Revenue and Profits:

Net Sales:

(Quarterly Results - )

Net Profit:

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

67.31%

3.50%

70.81%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Hannah Joseph for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

When is the next results date for Hannah Joseph Hospital Ltd?

The next results date for Hannah Joseph Hospital Ltd is scheduled for 29 May 2026....

Read full news article

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication

19-Jun-2026 | Source : BSE

We enclose copies of the newspaper advertisements published in The New Indian Express (English) and Dinamani (Tamil) on 19.06.2026 regarding the Notice of 15th Annual General meeting of the Company.

Reg. 34 (1) Annual Report.

18-Jun-2026 | Source : BSE

Submission of Annual Report for the Financial Year 2025-26 pursuant to Regulation 34 of the SEBI (LODR) Regulations 2015

Announcement under Regulation 30 (LODR)-Investor Presentation

16-Jun-2026 | Source : BSE

Investor Presentation under Regulation 30 read with schedule III of the SEBI (LODR) Regulations 2015

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

Hannah Joseph Hospital Ltd has declared 20% dividend, ex-date: 08 Jul 26

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

4.09

Debt to EBITDA (avg)

1.42

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.81

Tax Ratio

30.26%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

12.54%

ROCE (avg)

20.09%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.33

EV to EBIT

11.40

EV to EBITDA

8.34

EV to Capital Employed

2.59

EV to Sales

2.28

PEG Ratio

Dividend Yield

ROCE (Latest)

22.75%

ROE (Latest)

11.48%

Technicals key factors

Indicator

Weekly

Monthly

MACD

RSI

No Signal

Bollinger Bands

Bullish

KST

Dow Theory

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Feb 2026

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 2 FIIs (2.39%)

Promoter with highest holding

Mosesjoseph Arunkumar . (66.8%)

Highest Public shareholder

Negen Undiscovered Value Fund (3.68%)

Individual Investors Holdings

15.79%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Hannah Joseph"
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Mar 2026 is 16.36% vs 15.00% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Mar 2026 is 18.36% vs 64.10% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "49.51",
          "val2": "42.55",
          "chgp": "16.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "13.45",
          "val2": "11.76",
          "chgp": "14.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.36",
          "val2": "1.56",
          "chgp": "-12.82%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "6.06",
          "val2": "5.12",
          "chgp": "18.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.17%",
          "val2": "27.64%",
          "chgp": "-0.47%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Hannah Joseph"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 18.73% vs 22.27% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 55.06% vs 77.15% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "92.05",
          "val2": "77.53",
          "chgp": "18.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "25.20",
          "val2": "20.69",
          "chgp": "21.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.92",
          "val2": "3.47",
          "chgp": "-15.85%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "11.18",
          "val2": "7.21",
          "chgp": "55.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "27.38%",
          "val2": "26.69%",
          "chgp": "0.69%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Half Yearly Results Snapshot (Standalone) - Mar'26

Mar'26

Sep'25

Change(%)

Net Sales

49.51

42.55

16.36%

Operating Profit (PBDIT) excl Other Income

13.45

11.76

14.37%

Interest

1.36

1.56

-12.82%

Exceptional Items

0.00

Standalone Net Profit

6.06

5.12

18.36%

Operating Profit Margin (Excl OI)

27.17%

27.64%

-0.47%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Mar 2026 is 16.36% vs 15.00% in Sep 2025

Standalone Net Profit

Growth in half year ended Mar 2026 is 18.36% vs 64.10% in Sep 2025

All Half Yearly Results

Annual Results Snapshot (Standalone) - Mar'26

Mar'26

Mar'25

Change(%)

Net Sales

92.05

77.53

18.73%

Operating Profit (PBDIT) excl Other Income

25.20

20.69

21.80%

Interest

2.92

3.47

-15.85%

Exceptional Items

0.00

Standalone Net Profit

11.18

7.21

55.06%

Operating Profit Margin (Excl OI)

27.38%

26.69%

0.69%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2026 is 18.73% vs 22.27% in Mar 2025

Standalone Net Profit

YoY Growth in year ended Mar 2026 is 55.06% vs 77.15% in Mar 2025

All Annual Results

Company CV

About Hannah Joseph Hospital Ltd

Hannah Joseph Hospital Ltd

Micro Cap

Hospital

Hannah Joseph Hospital Limited is one of the first centres in Asia to adopt DTI Fibertracking 3.0, a revolutionary navigation tool for brain tumour surgeries. To provide comprehensive range of neurosurgery and neurology services, Mosesjoseph Arunkumar established a hospital in the name of `Hannah Joseph Hospital' as a sole proprietorship in Madurai town of Tamil Nadu, in 2008.

Company Coordinates

No Company Details Available